TDMS Study 05136-08 Pathology Tables
NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 CORE STUDY Facility: Battelle Northwest Chemical CAS #: 0000126-99-8 Lock Date: 04/14/94 Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 12.8 PPM 32 PPM 80 PPM ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Moribund Sacrifice 13 27 38 41 Natural Death 2 6 11 5 Accidently Killed 1 1 Survivors Terminal Sacrifice 35 16 1 2 Moribund Sacrifice 1 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Intestine Large, Colon (50) (47) (48) (49) Sarcoma 1 (2%) Intestine Small, Duodenum (49) (45) (42) (48) Intestine Small, Ileum (50) (45) (46) (49) Liver (50) (49) (50) (50) Hemangiosarcoma 1 (2%) 1 (2%) Hepatocellular Carcinoma 4 (8%) 10 (20%) 7 (14%) 15 (30%) Hepatocellular Carcinoma, Multiple 1 (2%) 7 (14%) 4 (8%) Hepatocellular Adenoma 12 (24%) 12 (24%) 9 (18%) 7 (14%) Hepatocellular Adenoma, Multiple 5 (10%) 7 (14%) 2 (4%) 9 (18%) Hepatocholangiocarcinoma 1 (2%) 1 (2%) Histiocytic Sarcoma 1 (2%) 2 (4%) 3 (6%) Sarcoma, Metastatic, Mesentery 1 (2%) 1 (2%) 2 (4%) Mesentery (10) (14) (27) (21) Hemangioma 2 (7%) 1 (5%) Hemangiosarcoma 4 (29%) 13 (48%) 4 (19%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (7%) Histiocytic Sarcoma 1 (4%) Sarcoma 4 (29%) 8 (30%) 3 (14%) Pancreas (49) (49) (48) (50) Hemangiosarcoma 1 (2%) Hemangiosarcoma, Metastatic, Mesentery 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Sarcoma, Metastatic, Mesentery 2 (4%) 2 (4%) Salivary Glands (50) (49) (50) (50) Sarcoma, Metastatic, Skin 1 (2%) Stomach, Forestomach (50) (49) (49) (50) Squamous Cell Carcinoma 1 (2%) Squamous Cell Papilloma 4 (8%) Stomach, Glandular (50) (48) (49) (50) Sarcoma, Metastatic, Mesentery 1 (2%) 2 (4%) 1 (2%) Page 2 NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 12.8 PPM 32 PPM 80 PPM ____________________________________________________________________________________________________________________________________ ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (49) (50) (50) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (48) (49) (50) Hemangiosarcoma, Metastatic, Mesentery 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Adrenal Medulla (50) (48) (48) (50) Pheochromocytoma Malignant 1 (2%) Pheochromocytoma Benign 1 (2%) 1 (2%) Islets, Pancreatic (49) (49) (48) (50) Adenoma 1 (2%) 2 (4%) Pituitary Gland (49) (48) (48) (50) Pars Distalis, Adenoma 4 (8%) 6 (13%) 4 (8%) 4 (8%) Pars Intermedia, Adenoma 1 (2%) 1 (2%) Thyroid Gland (50) (49) (49) (50) Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%) Follicular Cell, Carcinoma 2 (4%) Thyroglossal Duct, Adenoma 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Ovary (48) (47) (47) (49) Cystadenoma 1 (2%) 1 (2%) 1 (2%) Hemangiosarcoma 1 (2%) Histiocytic Sarcoma 2 (4%) 1 (2%) Luteoma 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Teratoma Malignant 1 (2%) Uterus (50) (49) (50) (50) Hemangioma 2 (4%) Hemangiosarcoma 2 (4%) Histiocytic Sarcoma 1 (2%) 2 (4%) 2 (4%) Leiomyosarcoma 1 (2%) Polyp Stromal 2 (4%) 4 (8%) 2 (4%) 3 (6%) Sarcoma, Metastatic, Mesentery 1 (2%) Vagina (1) Page 3 NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 12.8 PPM 32 PPM 80 PPM ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM - cont Sarcoma 1 (100%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (49) (49) (50) Hemangiosarcoma 1 (2%) 1 (2%) Lymph Node (4) (3) (5) (2) Iliac, Hemangiosarcoma, Metastatic, Mesentery 1 (20%) Iliac, Sarcoma, Metastatic, Mesentery 1 (50%) Lymph Node, Bronchial (32) (31) (34) (38) Histiocytic Sarcoma 1 (3%) Sarcoma, Metastatic, Mesentery 1 (3%) Lymph Node, Mandibular (32) (40) (33) (40) Lymph Node, Mesenteric (48) (45) (48) (46) Hemangiosarcoma 2 (4%) 1 (2%) 1 (2%) Hemangiosarcoma, Metastatic, Mesentery 3 (6%) Histiocytic Sarcoma 2 (4%) Sarcoma 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) 4 (8%) Sarcoma, Metastatic, Skin 1 (2%) Sarcoma, Metastatic, Intestine Large, Colon 1 (2%) Lymph Node, Mediastinal (38) (44) (45) (40) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (3%) 1 (3%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Sarcoma, Metastatic, Mesentery 1 (3%) Sarcoma, Metastatic, Skin 1 (3%) Spleen (50) (49) (49) (50) Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Thymus (44) (35) (39) (39) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (3%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (49) (49) (50) (50) Adenoacanthoma 1 (2%) 3 (6%) 2 (4%) Adenoma 1 (2%) 1 (2%) Carcinoma 3 (6%) 4 (8%) 6 (12%) 11 (22%) Carcinoma, Multiple 1 (2%) 1 (2%) Skin (49) (49) (50) (50) Basal Cell Adenoma 1 (2%) Squamous Cell Papilloma 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 2 (4%) 1 (2%) 2 (4%) 1 (2%) Page 4 NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 12.8 PPM 32 PPM 80 PPM ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM - cont Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) Subcutaneous Tissue, Sarcoma 10 (20%) 10 (20%) 16 (32%) Subcutaneous Tissue, Sarcoma, Multiple 1 (2%) 1 (2%) 2 (4%) Subcutaneous Tissue, Sarcoma, Metastatic, Mesentery 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (49) (50) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Skeletal Muscle (2) (1) Sarcoma, Metastatic, Mesentery 1 (50%) Sarcoma, Metastatic, Skin 1 (50%) 1 (100%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM None ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Larynx (50) (49) (50) (50) Lung (50) (49) (50) (50) Adenoacanthoma, Metastatic, Mammary Gland 3 (6%) Alveolar/Bronchiolar Adenoma 2 (4%) 10 (20%) 17 (34%) 10 (20%) Alveolar/Bronchiolar Adenoma, Multiple 6 (12%) 12 (24%) 16 (32%) Alveolar/Bronchiolar Carcinoma 2 (4%) 8 (16%) 8 (16%) 11 (22%) Alveolar/Bronchiolar Carcinoma, Multiple 6 (12%) 8 (16%) 17 (34%) Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%) Carcinoma, Metastatic, Mammary Gland 2 (4%) 2 (4%) Carcinoma, Metastatic, Zymbal's Gland 2 (4%) Hemangiosarcoma, Metastatic, Mesentery 1 (2%) 2 (4%) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) 1 (2%) 1 (2%) 4 (8%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) Histiocytic Sarcoma 1 (2%) 2 (4%) Sarcoma, Metastatic, Mesentery 2 (4%) 1 (2%) Sarcoma, Metastatic, Skin 2 (4%) 1 (2%) 2 (4%) Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) 2 (4%) Mediastinum, Hemangiosarcoma 1 (2%) Mediastinum, Sarcoma, Metastatic, Mesentery 1 (2%) 1 (2%) Mediastinum, Sarcoma, Metastatic, Skin 1 (2%) 1 (2%) Nose (50) (49) (49) (50) Respiratory Epithelium, Adenoma 1 (2%) Page 5 NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 12.8 PPM 32 PPM 80 PPM ____________________________________________________________________________________________________________________________________ ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (2) (6) (4) (9) Adenoma 1 (50%) 3 (50%) 3 (75%) 8 (89%) Carcinoma 1 (50%) 2 (33%) 1 (11%) Zymbal's Gland (3) Carcinoma 3 (100%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (49) (49) (50) Hemangiosarcoma, Metastatic, Mesentery 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Mesentery 2 (4%) Urinary Bladder (50) (47) (46) (47) Hemangiosarcoma 1 (2%) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Mesentery 2 (4%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Histiocytic Sarcoma 1 (2%) 2 (4%) 3 (6%) Lymphoma Malignant 7 (14%) 7 (14%) 3 (6%) 1 (2%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 6 NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE CONTROL 12.8 PPM 32 PPM 80 PPM ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 34 47 50 48 Total Primary Neoplasms 55 124 151 160 Total Animals with Benign Neoplasms 22 32 38 42 Total Benign Neoplasms 31 53 59 66 Total Animals with Malignant Neoplasms 20 42 49 48 Total Malignant Neoplasms 24 71 92 94 Total Animals with Metastatic Neoplasms 3 8 23 15 Total Metastatic Neoplasm 3 18 40 27 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 7 NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 12.8 PPM 32 PPM 80 PPM ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Moribund Sacrifice 15 16 26 34 Natural Death 8 7 10 3 Survivors Terminal Sacrifice 27 27 14 13 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Gallbladder (41) (40) (37) (40) Intestine Large, Cecum (48) (44) (45) (48) Hemangioma 1 (2%) Muscularis, Leiomyoma 1 (2%) Intestine Small, Jejunum (46) (43) (47) (49) Intestine Small, Ileum (46) (45) (46) (48) Liver (50) (50) (50) (49) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Cholangiocarcinoma 1 (2%) Hemangiosarcoma 2 (4%) 5 (10%) 6 (12%) 8 (16%) Hepatoblastoma 2 (4%) 3 (6%) 1 (2%) Hepatocellular Carcinoma 10 (20%) 18 (36%) 18 (36%) 16 (33%) Hepatocellular Carcinoma, Multiple 14 (28%) 10 (20%) 19 (38%) 17 (35%) Hepatocellular Adenoma 8 (16%) 11 (22%) 12 (24%) 11 (22%) Hepatocellular Adenoma, Multiple 14 (28%) 5 (10%) 7 (14%) 10 (20%) Hepatocholangiocarcinoma 1 (2%) 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Sarcoma 1 (2%) Mesentery (2) (8) (16) (11) Hemangioma 1 (6%) 2 (18%) Hemangiosarcoma 3 (38%) 13 (81%) 7 (64%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (13%) Sarcoma, Metastatic, Liver 1 (13%) Oral Mucosa (1) Gingival, Squamous Cell Carcinoma 1 (100%) Pancreas (50) (48) (49) (50) Hemangiosarcoma 1 (2%) Hemangiosarcoma, Metastatic, Mesentery 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) Sarcoma, Metastatic, Liver 1 (2%) Stomach, Forestomach (50) (48) (49) (50) Squamous Cell Carcinoma 1 (2%) Page 8 NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 12.8 PPM 32 PPM 80 PPM ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Squamous Cell Papilloma 1 (2%) 2 (4%) 4 (8%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (49) (50) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 2 (4%) Hemangioma 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (49) (50) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 2 (4%) Capsule, Adenoma 1 (2%) Adrenal Medulla (50) (49) (50) (49) Pheochromocytoma Malignant 1 (2%) Pheochromocytoma Benign 1 (2%) 1 (2%) Pituitary Gland (49) (47) (47) (48) Pars Distalis, Adenoma 1 (2%) Thyroid Gland (50) (49) (50) (50) Follicular Cell, Adenoma 1 (2%) 1 (2%) 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Epididymis (50) (49) (50) (50) Hemangiosarcoma, Metastatic, Mesentery 1 (2%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) Leiomyoma 1 (2%) Leiomyosarcoma 1 (2%) Preputial Gland (50) (47) (47) (50) Hemangiosarcoma 2 (4%) Prostate (49) (48) (48) (49) Hemangiosarcoma, Metastatic, Mesentery 1 (2%) Seminal Vesicle (49) (48) (49) (48) Sarcoma, Metastatic, Liver 1 (2%) Testes (50) (49) (50) (50) Page 9 NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 12.8 PPM 32 PPM 80 PPM ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM - cont Hemangiosarcoma 1 (2%) Interstitial Cell, Adenoma 1 (2%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (49) (50) (50) Hemangiosarcoma 1 (2%) 2 (4%) 1 (2%) Histiocytic Sarcoma 1 (2%) Lymph Node (1) (2) (3) Renal, Hemangiosarcoma 1 (33%) Lymph Node, Bronchial (32) (23) (33) (28) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 4 (14%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (4%) Histiocytic Sarcoma 1 (3%) Lymph Node, Mandibular (32) (28) (27) (34) Histiocytic Sarcoma 1 (4%) Lymph Node, Mesenteric (47) (48) (46) (48) Hemangiosarcoma 1 (2%) Histiocytic Sarcoma 2 (4%) 1 (2%) Lymph Node, Mediastinal (34) (38) (37) (37) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (3%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (3%) Sarcoma, Metastatic, Liver 1 (3%) Spleen (50) (49) (50) (50) Hemangiosarcoma 2 (4%) 2 (4%) 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Thymus (34) (28) (25) (34) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (3%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (49) (48) (50) (50) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) 3 (6%) 1 (2%) 7 (14%) Subcutaneous Tissue, Hemangiosarcoma, Multiple 1 (2%) Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) 1 (2%) Subcutaneous Tissue, Sarcoma, Multiple 1 (2%) ____________________________________________________________________________________________________________________________________ Page 10 NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 12.8 PPM 32 PPM 80 PPM ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (50) (50) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Hemangiosarcoma 1 (2%) Skeletal Muscle (1) Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM None ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (50) (50) (50) Alveolar/Bronchiolar Adenoma 8 (16%) 12 (24%) 15 (30%) 15 (30%) Alveolar/Bronchiolar Adenoma, Multiple 6 (12%) 7 (14%) 13 (26%) Alveolar/Bronchiolar Carcinoma 4 (8%) 8 (16%) 13 (26%) 13 (26%) Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%) 4 (8%) 10 (20%) 15 (30%) Hemangiosarcoma, Metastatic, Mesentery 1 (2%) Hemangiosarcoma, Metastatic, Skin 1 (2%) Hepatoblastoma, Metastatic, Liver 1 (2%) 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 8 (16%) 10 (20%) 5 (10%) 4 (8%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Liver 1 (2%) Bronchiole, Adenoma 1 (2%) Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 4 (8%) Mediastinum, Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) 1 (2%) Nose (50) (48) (50) (50) Adenoma 1 (2%) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Carcinoma, Metastatic, Harderian Gland 1 (2%) Respiratory Epithelium, Adenoma 1 (2%) Trachea (50) (48) (50) (50) Adenoma 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ Page 11 NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 12.8 PPM 32 PPM 80 PPM ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (2) (5) (11) (12) Adenoma 2 (100%) 5 (100%) 8 (73%) 9 (75%) Carcinoma 2 (18%) 2 (17%) Bilateral, Adenoma 1 (8%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (49) (50) (50) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Hemangiosarcoma 1 (2%) Hemangiosarcoma, Metastatic, Mesentery 4 (8%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Renal Tubule, Adenoma 1 (2%) 1 (2%) 3 (6%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Histiocytic Sarcoma 3 (6%) 2 (4%) 1 (2%) Lymphoma Malignant 2 (4%) 2 (4%) 2 (4%) 4 (8%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 12 NTP Experiment-Test: 05136-08 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC CHLOROPRENE Date: 10/04/96 Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 09:52:49 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE CONTROL 12.8 PPM 32 PPM 80 PPM ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 48 48 50 50 Total Primary Neoplasms 78 106 156 172 Total Animals with Benign Neoplasms 31 31 38 43 Total Benign Neoplasms 38 43 59 72 Total Animals with Malignant Neoplasms 34 40 50 47 Total Malignant Neoplasms 40 63 97 100 Total Animals with Metastatic Neoplasms 8 13 12 12 Total Metastatic Neoplasm 8 22 14 31 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 13 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------